S&H LECT1 (1).ppt
- 2. • SEDATIVES – reduce anxiety and exert a calming effect • HYPNOTICS - produces drowsiness and facilitates the onset and maintenance of a state of sleep.
- 5. Non Benzodiazepine hypnotics • ZOLPIDEM • ZALEPLON • ZOPICLONE (ESZOPICLONE) Miscellaneous • MELATONIN • RAMELTEON
- 6. BARBITURATES CLASSIFIED ACCORDING TO THEIR DURATIONS OF ACTION
- 11. Barbiturates • enhance the binding of GABA to GABAA receptors • Prolonging duration • Only α and β (not ϒ ) subunits are required for barbiturate action • Narrow therapeutic index • in small doses, barbiturates increase reactions to painful stimuli. • Hence, they cannot be relied on to produce sedation or sleep in the presence of even moderate pain. Bezodiazepines • enhance the binding of GABA to GABAA receptors • increasing the frequency • Unlike barbiturates, benzodiazepines do not activate GABAA receptors directly
- 12. BARBITURATES Mechanism of Action- Bind to specific GABAA receptor subunits at CNS neuronal synapses facilitating GABA-mediated chloride ion channel opening, enhance membrane hyperpolarization. Effects- Dose-dependent depressant effects on the CNS including • Sedation • Relief of anxiety • Amnesia • Hypnosis • Anaesthesia • Coma • Respiratory depression steeper dose-response relationship than benzodiazepines
- 13. BARBITURATES ACTIONS 1. Depression of CNS: At low doses, the barbiturates produce sedation (calming effect, reducing excitement). 2. Respiratory depression: Barbiturates suppress the hypoxic and chemoreceptor response to CO2, and overdosage is followed by respiratory depression and death. 3. Enzyme induction: Barbiturates induce P450 microsomal enzymes in the liver.
- 14. BARBITURATES PHARMACOKINETICS • All barbiturates redistribute in the body. • Barbiturates are metabolized in the liver, and inactive metabolites are excreted in the urine. • They readily cross the placenta and can depress the fetus. • Toxicity: Extensions of CNS depressant effects dependence liability > benzodiazepines. • Interactions: Additive CNS depression with ethanol and many other drugs induction of hepatic drug-metabolizing enzymes.
- 15. THERAPEUTIC USES ANESTHESIA (THIOPENTAL, METHOHEXITAL) • Selection of a barbiturate is strongly influenced by the desired duration of action. • The ultrashort-acting barbiturates, such as thiopental, are used intravenously to induce anesthesia. ANXIETY • Barbiturates have been used as mild sedatives to relieve anxiety, nervous tension, and insomnia. When used as hypnotics, they suppress REM sleep more than other stages. However, most have been replaced by the benzodiazepines.
- 16. THERAPEUTIC USES ANTICONVULSANT: (PHENOBARBITAL, MEPHOBARBITAL) • Phenobarbital is used in long-term management of tonic-clonic seizures, status epilepticus, and eclampsia. • Phenobarbital has been regarded as the drug of choice for treatment of young children with recurrent febrile seizures. • However, phenobarbital can depress cognitive performance in children, and the drug should be used cautiously. • Phenobarbital has specific anticonvulsant activity that is distinguished from the nonspecific CNS depression.
- 17. ADVERSE EFFECTS 1. CNS: Barbiturates cause drowsiness, impaired concentration. 2. Drug hangover: Hypnotic doses of barbiturates produce a feeling of tiredness well after the patient wakes. 3. Barbiturates induce the P450 system. 4. By inducing aminolevulinic acid (ALA) synthetase, barbiturates increase porphyrin synthesis, and are contraindicated in patients with acute intermittent porphyria.
- 18. ADVERSE EFFECTS 5. Physical dependence: Abrupt withdrawal from barbiturates may cause tremors, anxiety, weakness, restlessness, nausea and vomiting, seizures, delirium, and cardiac arrest. 6. Poisoning: Barbiturate poisoning has been a leading cause of death resulting from drug overdoses for many decades. It may be due to automatism. • Severe depression of respiration is coupled with central cardiovascular depression, and results in a shock-like condition with shallow, infrequent breathing.
- 19. ADVERSE EFFECTS
- 20. THE TREATMENT OF ACUTE BARBITURATE INTOXICATION Treatment includes artificial respiration and purging the stomach of its contents if the drug has been recently taken. • No specific barbiturate antagonist is available. • General supportive measures. • Hemodialysis or hemoperfusion is necessary only rarely. • Use of CNS stimulants is contraindicated because they increase the mortality rate.
- 21. THE TREATMENT OF ACUTE BARBITURATE INTOXICATION • If renal and cardiac functions are satisfactory, and the patient is hydrated, forced diuresis and alkalinization of the urine will hasten the excretion of phenobarbital. • In the event of renal failure - hemodialysis • circulatory collapse is a major threat. So hypovolemia must be corrected & blood pressure can be supported with dopamine. • Acute renal failure consequent to shock and hypoxia accounts for perhaps one-sixth of the deaths.
- 22. BENZODIAZEPINES
- 23. COMPARISON OF THE DURATIONS OF ACTION OF THE BENZODIAZEPINES
- 24. Effects of benzodiazepine • On increasing the dose sedation progresses to hypnosis and then to stupor. • But the drugs do not cause a true general anesthesia because -awareness usually persists -immobility sufficient to allow surgery cannot be achieved. • However at "preanesthetic" doses, there is amnesia.
- 25. Effects on the (EEG) and Sleep Stages • ↓ sleep latency • ↓ number of awakenings • ↓ time spent in stage 0, 1, 3, 4 • ↓ time spent in REM sleep (↑number of cycles of REM sleep) • ↑ total sleep time (largely by increasing the time spent in stage 2)
- 26. • Respiration-Hypnotic doses of benzodiazepines are without effect on respiration in normal subjects • CVS-In preanesthetic doses, all benzodiazepines decrease blood pressure and increase heart rate
- 27. PHARMACOKINETICS • A short elimination t1/2 is desirable for hypnotics, although this carries the drawback of increased abuse liability and severity of withdrawal after drug discontinuation. • Most of the BZDs are metabolized in the liver to produce active products (thus long duration of action). • After metabolism these are conjugated and are excreted via kidney.
- 28. ADVERSE EFFECTS • Light-headedness • Fatigue • Increased reaction time • Motor incoordination • Impairment of mental and motor functions • Confusion • Antero-grade amnesia • Cognition appears to be affected less than motor performance. • All of these effects can greatly impair driving and other psychomotor skills, especially if combined with ethanol.
- 29. FLUMAZENIL: A BENZODIAZEPINE RECEPTOR ANTAGONIST • competitively antagonism • Flumazenil antagonizes both the electrophysiological and behavioral effects of agonist and inverse-agonist benzodiazepines and β -carbolines. • Flumazenil is available only for intravenous administration. • On intravenous administration, flumazenil is eliminated almost entirely by hepatic metabolism to inactive products with a t1/2 of ~1 hour; the duration of clinical effects usually is only 30-60 minutes.
- 30. FLUMAZENIL: A BENZODIAZEPINE RECEPTOR ANTAGONIST PRIMARY INDICATIONS FOR THE USE OF FLUMAZENIL ARE:- • Management of suspected benzodiazepine overdose. • Reversal of sedative effects produced by benzodiazepines administered during either general anesthesia. The administration of a series of small injections is preferred to a single bolus injection. • A total of 1 mg flumazenil given over 1-3 minutes usually is sufficient to abolish the effects of therapeutic doses of benzodiazepines. • Patients with suspected benzodiazepine overdose should respond adequately to a cumulative dose of 1-5 mg given over 2-10 minutes; • A lack of response to 5 mg flumazenil strongly suggests that a benzodiazepine is not the major cause of sedation.
- 31. Novel Benzodiazepine Receptor Agonists • Z compounds zolpidem , zaleplon , zopiclone and eszopiclone • structurally unrelated to each other and to benzodiazepines • therapeutic efficacy as hypnotics is due to agonist effects on the benzodiazepine site of the GABAA receptor • Compared to benzodiazepines, Z compounds are -less effective as anticonvulsants or muscle relaxants -which may be related to their relative selectivity for GABAA receptors containing the α1 subunit.
- 32. Novel Benzodiazepine Receptor Agonists • The clinical presentation of overdose with Z compounds is similar to that of benzodiazepine overdose and can be treated with the benzodiazepine antagonist flumazenil. • Zaleplon and zolpidem are effective in relieving sleep- onset insomnia. Both drugs have been approved by the FDA for use for up to 7-10 days at a time. • Zaleplon and zolpidem have sustained hypnotic efficacy without occurrence of rebound insomnia on abrupt discontinuation.
- 33. ZALEPLON • Its plasma t1/2 is ~1 hours • approved for use immediately at bedtime or when the patient has difficulty falling asleep after bedtime. ZOLPIDEM • Its plasma t1/2 is ~2 hours • Cover most of a typical 8-hour sleep period, and is presently approved for bedtime use only.
- 34. Eszopiclone • Used for the long-term treatment of insomnia and for sleep maintenance. • t1/2 of ~6 hours.
- 35. MELATONIN CONGENERS RAMELTEON • Synthetic tricyclic analog of MELATONIN. • It was approved for the treatment of insomnia, specifically sleep onset difficulties. MECHANISM OF ACTION • Melatonin levels in the suprachiastmatic nucleus rise and fall in a circadian fashion concentrations increasing in the evening as an individual prepares for sleep, and then reaching a plateau and ultimately decreasing as the night progresses.
- 36. MELATONIN CONGENERS Mechanism of Action • Two GPCRs for melatonin, MT1 and MT2, are found in the suprachiasmatic nucleus, each playing a different role in sleep. • RAMELTEON binds to both MT1 and MT2 receptors with high affinity. • Binding of Melatonin to MT1 receptors promotes the onset of sleep. • Binding of Melatonin to MT2 receptors shifts the timing of the circadian system. • RAMELTEON is efficacious in combating both transient and chronic insomnia
- 37. Prescribing Guidelines for the Management of Insomnia Hypnotics that act at GABAA receptors, including the benzodiazepine hypnotics and the newer agents zolpidem, zopiclone, and zaleplon, are preferred to barbiturates because they have a • Greater therapeutic index • Less toxic in overdose • Have smaller effects on sleep architecture • Less abuse potential. Compounds with a shorter t1/2 are favored in patients with sleep-onset insomnia but without significant daytime anxiety who need to function at full effectiveness during the day. • These compounds also appropriate for the elderly because of a decreased risk of falls and respiratory depression. • One should be aware that early-morning awakening, rebound daytime anxiety, and amnestic episodes also may occur. • These undesirable side effects are more common at higher doses of the benzodiazepines.
- 38. Prescribing Guidelines for the Management of Insomnia • Benzodiazepines with longer t1/2 are favored for patients - --- who have significant daytime anxiety and ----- who may be able to tolerate next-day sedation. • However can be associated with -next-day cognitive impairment -delayed daytime cognitive impairment (after 2-4 weeks of treatment) as a result of drug accumulation with repeated administration. • Older agents such as barbiturates, chloral hydrate, and meprobamate have high abuse potential and are dangerous in overdose.
- 39. CATEGORIES OF INSOMNIA Transient insomnia Short-term insomnia Long-term insomnia •Lasts <3 days •---Caused by a brief environmental or situational stressor. •---Respond to attention to sleep hygiene rules. •--- Hypnotics should be used at the lowest dose and for only 2-3 nights. •3 days to 3 weeks •--- Caused by a personal stressor such as illness, grief, or job problems. •---Sleep hygiene education is the first step. •---Hypnotics may be used adjunctively for 7-10 nights. •---- Hypnotics are best used intermittently during this time, with the patient skipping a dose after 1-2 nights of good sleep. •lasted for >3 weeks •---No specific stressor may be identifiable. •---A more complete medical evaluation is necessary in these patients, but most do not need an all-night sleep study.
- 40. LONG-TERM INSOMNIA Nonpharmacological treatments are important for all patients with long- term insomnia.These include • Reduced caffeine intake • Avoidance of alcohol • Adequate exercise • Relaxation training • Behavioral-modification approaches, such as sleep-restriction and stimulus-control therapies. • Nonpharmacological treatments for insomnia have been found to be particularly effective in reducing sleep-onset latency and time awake after sleep onset.
- 41. Management of Patients after Long-Term Treatment with Hypnotic Agents • If a benzodiazepine has been used regularly for >2 weeks, it should be tapered rather than discontinued abruptly. • In some patients on hypnotics with a short t1/2, it is easier to switch first to a hypnotic with a long t1/2 and then to taper. • The onset of withdrawal symptoms from medications with a long t1/2 may be delayed. • Consequently, the patient should be warned about the symptoms associated with withdrawal effects.
- 42. Atypical Anxiolytics • Buspiron • Ipsapirone • Gepirone • Buspirone relieves anxiety -without causing marked sedative, hypnotic, or euphoric effects. - no anticonvulsant or muscle relaxant properties. • Buspirone does not interact directly with GABAergic systems. • Anxiolytic effects of buspirone is by acting as a partial agonist at brain 5-HT1A receptors.
- 43. • the anxiolytic effects of buspirone may take more than a week • unsuitable for management of acute anxiety states • no rebound anxiety or withdrawal signs on abrupt discontinuance • The drug is not effective in blocking the acute withdrawal syndrome resulting from abrupt cessation of use of benzodiazepines or other sedative-hypnotics • Buspirone has minimal abuse liability • The drug is used in generalized anxiety states • but is less effective in panic disorders
- 44. MCQs Q1. Sleep promoting effect of ramelteon is mediated by receptor: • A. GABAA receptor • B. Opiate receptors • C. GABAB receptor • D. Melatonin receptors MT1 and MT2 • Ans- D
- 45. Q2. Which one of the following effects is NOT seen with barbiturates? • A. Analgesic • B. Anticonvulsant • C. Induction and maintenance of anaesthesia • D. Sedation • Ans- A
- 46. Q3. An ideal hypnotic drug should NOT have: • A. rapid onset of action • B. sustained effect throughout the night • C. without any residual effect in the following morning • D. increase in sleep latency • Ans- D
- 47. Q4. True statement about effect of bezodiazepines on sleep is: • A. Time spent in stage 2 is decreased • B. Time spent in stages 1, 3 and 4 is increased • C. Shortening of REM sleep • D. Increase sleep latency • Ans- C
- 48. Q5. Beta carboline at benzodiazepine receptor act as: • A. Agonist • B. Inverse agonist • C. Antagonist • D. Partial agonist • Ans- B
- 49. Q6. Benzodiazepine antagonist is: • A. Naloxone • B. Zolpidem • C. Nalorphine • D. Flumazenil • Ans- D
- 50. Q7. Benzodiazepines act by: • A. Activating GABAA receptors directly • B. Modulating the effects of GABA on GABAA receptors • C. Antagonistic effect on GABAA receptors • D. GABA mimetic effect • Ans- B
- 51. Q8. Administration of barbiturate is contraindicated in: • A. Kernicterus • B. Anxiety • C. Epilepsy • D. Acute Intermittant porphyria • Ans-D
- 52. Q9. Which is NOT true about Flumazenil? • A. Acts on GABAA receptor • B. Specific antagonist of benzodiazepine • C. Given intravenously • D. May be used in barbiturate poisoning • Ans- D
- 53. Q10. True statement about zolpidem: • A. Relieve sleep onset insomnia • B. Cause profound rebound insomnia • C. Cause profound REM suppression • D. Has strong anticonvulsant effect • Ans- A
- 54. Bibliography • Essentials of Medical Pharmacology -7th edition by KD Tripathi • Goodman & Gilman's the Pharmacological Basis of Therapeutics 12th edition by Laurence Brunton (Editor) • Lippincott's Illustrated Reviews: Pharmacology - 6th edition by Richard A. Harvey • Basic and Clinical pharmacology 11th edition by Bertram G Katzung • Rang & Dale's Pharmacology -7th edition by Humphrey P. Rang • Clinical Pharmacology 11th edition By Bennett and Brown, Churchill Livingstone • Principles of Pharmacology 2nd edition by HL Sharma and KK Sharma • Review of Pharmacology by Gobind Sparsh
- 55. THANKS